Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bezafibrate plus obeticholic acid in primary biliary cholangitis
2024-513584-77-00Phase 2Completed
- Sponsor
- Intercept Pharmaceuticals
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of obeticholic acid and bezafibrate in primary biliary cholangitis (PBC), sponsored by Intercept Pharmaceuticals. Primary endpoint: Change in alkaline phosphatase (ALP) from baseline to Week 12. Started Jul 2024; status: completed.
02
Drugs
obeticholic acidbezafibrate
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2024-513584-77-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513584-77-00.